Home›Trial›NCT04348708
NCT04348708Enrolling by invitation

Long-Term Follow Up Study of Subjects Previously Administered HMI 102

Study Summary

An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102

Conditions
PhenylketonuriaPAH Deficiency
Interventions / Drugs
HMI-102
View on ClinicalTrials.gov ↗
Sponsor
FIXX
Homology Medicines
Gene Therapy
F9/100
Study Details
Enrollment21 participants
Primary Completion2026-01-30
Lead SponsorHomology Medicines, Inc
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: Enrolling by invitation.

Primary completion: 2026-01-30
Enrolled: 21 participants
Sponsor Catalyst Profile

Homology Medicines (FIXX) is the sponsoring company for this trial. BiotechSign currently grades this company F (9/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

FIXX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence